ClinicalTrials.Veeva

Menu
The trial is taking place at:
E

Epic Medical Research | Red Oak, TX

Veeva-enabled site

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)

Lilly logo

Lilly

Status and phase

Active, not recruiting
Phase 3

Conditions

Overweight
Obesity
Type 2 Diabetes

Treatments

Drug: Orforglipron
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT05872620
18560 (Other Identifier)
U1111-1289-8799 (Other Identifier)
2022-502837-24-00 (Other Identifier)
J2A-MC-GZGQ (Other Identifier)

Details and patient eligibility

About

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.

Enrollment

1,500 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Have a body mass index (BMI) ≥27.0 kilogram/square meter (kg/m²).

  • Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.

  • Have a diagnosis of Type 2 Diabetes (T2D), with HbA1c ≥7% (≥53 mmol/mol) to ≤10% (86 mmol/mol) and are on stable treatment for T2D for at least 90 days prior to screening, consisting of:

    • either diet/exercise alone or
    • up to 3 oral antihyperglycemic medications (excluding dipeptidyl peptidase IV inhibitors (DPP-4i) or glucagon-like peptide-1 (GLP-1) receptor agonists (RA).

Exclusion criteria

  • Have Type 1 Diabetes (T1D), history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2D.
  • Have a self-reported change in body weight >5 kg (11 pounds) within 90 days prior to screening.
  • Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema (for example, laster photocoagulation or intravitreal injections of anti-vascular endothelial growth factor inhibitors).
  • Have family (first-degree relative) or personal history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia 2 (MEN2) syndrome.
  • Have had a history of chronic or acute pancreatitis.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

1,500 participants in 4 patient groups, including a placebo group

Orforglipron Dose 1
Experimental group
Description:
Participants will receive orforglipron administered orally.
Treatment:
Drug: Orforglipron
Orforglipron Dose 2
Experimental group
Description:
Participants will receive orforglipron administered orally.
Treatment:
Drug: Orforglipron
Orforglipron Dose 3
Experimental group
Description:
Participants will receive orforglipron administered orally.
Treatment:
Drug: Orforglipron
Placebo
Placebo Comparator group
Description:
Participants will receive placebo
Treatment:
Drug: Placebo

Trial contacts and locations

138

Loading...

Central trial contact

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems